As of February 27, 2023, around 77.5 percent of the population in Japan received the second dose of coronavirus disease (COVID-19) vaccination. At the same time, approximately 68.4 percent of the population had a booster shot.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

As of February 2023, about 95.8 percent of citizens aged 90 to 99 years in Japan received the third dose of coronavirus disease (COVID-19) vaccinations. The overall share of around 68.4 percent of inhabitants in Japan was vaccinated with the third dose as of the same day.

As of March 16, 2022, close to 79 percent of inhabitants in Akita Prefecture received the second dose of coronavirus disease (COVID-19) vaccination, the highest vaccination rate among all 47 prefectures in Japan. In terms of the booster shot, Yamaguchi Prefecture recorded at around 40.6 percent.

The distribution of COVID-19 vaccination in Japan has begun on February 17, 2021, mainly for health professionals. On April 12, 2021, the government started the vaccine administration for citizens aged 65 and older.

Forecast: Measles Vaccination Rates Among Children in Japan 2022 - 2026 Discover more data with ReportLinker!

This study evaluated pneumococcal vaccination status using evaluable data collected from 445 of 1,313 managing directors of elderly care facilities in Japan through an online survey (September 5, 2022-November 25, 2022; UMIN000048747); comparisons were made with the influenza (2021–2022 vaccination only) and coronavirus disease 2019 (COVID-19) vaccination status. Among facilities who kept pneumococcal vaccination records (n = 42), the mean pneumococcal vaccination rate was 31.1%, with the rate being higher for the influenza (93.1%; n = 234) and COVID-19 (94.3%; n = 285) vaccines. Overall, excluding facilities that answered that the corresponding vaccine status at their sites was unknown, the percentage of facilities with high vaccination rates (80% to 100%) was substantially higher for the influenza (80.5%; 351/436) and COVID-19 (89.6%; 396/442) vaccines than for the pneumococcal vaccine (6.5%; 24/370). Multivariable analysis showed that major factors associated with a high pneumococcal vaccination rate (≥15%) were “managing director’s willingness to recommend” and “pneumococcal vaccination request from the residents.” The most common reason for their willingness to recommend the pneumococcal vaccine was that it is an effective disease prevention strategy (83.3%; 65/78) and for their unwillingness to recommend the pneumococcal vaccine was the inability to understand the effectiveness of the vaccine (43.6%; 17/39). In conclusion, there is a need to improve pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as increasing awareness and encouraging pneumococcal vaccine recommendation among managing directors, especially for residents not eligible for the national subsidy program, and providing regular training on the pneumococcal vaccine for staff and residents are required. Pneumococcal vaccination rates and factors associated with the vaccination of elderly care facility residents are important for policymakers and academia when considering the development and implementation of vaccination programs and guidelines for the management of residents in these facilities. This study evaluated how many elderly people living in care facilities in Japan got pneumococcal vaccine, comparing it with their rates of getting influenza (2021–2022 vaccination only) and COVID-19 vaccines. The information was collected from managing directors of these facilities through an online survey (September 5, 2022-November 25, 2022). Of the 1,313 managing directors contacted, 445 responded. Among the 42 facilities that had recorded pneumococcal vaccination history of their residents, the average vaccination rate was 31.1%, which was much lower than the rates for influenza (93.1%) and COVID-19 (94.3%) vaccines. Only a small percentage of facilities (6.5%) had high (80% to 100%) pneumococcal vaccination rates, while most had high rates for influenza (80.5%) and COVID-19 vaccines (89.6%). Managing directors recommending the pneumococcal vaccine and residents requesting it were major factors in higher vaccination rates. Most managing directors who recommended pneumococcal vaccine believed it was effective, while those who did not recommend often did not understand its effectiveness. In conclusion, there is a need to increase pneumococcal vaccination rates in elderly care facilities in Japan. Strategies such as raising awareness among managing directors, encouraging them to recommend the vaccine (especially for residents not covered by national subsidy programs), and providing regular training on the vaccine to staff and residents are required.

In 2018, the rate of children vaccinated against diphtheria, tetanus, and pertussis in Japan reached about ** percent, up ***** percentage points from 2015.

Actual value and historical data chart for Japan Immunization Bcg Percent Of One Year Old Children

Immunization, measles (% of children ages 12-23 months) in Japan was reported at 95 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Immunization, measles (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

Forecast: Total Influenza Vaccination Rates in Japan 2022 - 2026 Discover more data with ReportLinker!

This statistic presents the results of a survey on perceived percentage of infants who receive all the WTO recommended vaccinations in Japan as of October 2018. According to data published by Ipsos, Japanese respondents underestimated the coverage of vaccinations of infants in Japan. On average, the respondents thought that around ** out of every 100 Japanese infants under 12 months have had all the recommended vaccines for diphtheria, tetanus, whooping cough, polio, and measles, when the actual infant vaccination coverage was ** percent in Japan.

IntroductionAddresing vaccine hesitancy is considered an important goal in management of the COVID-19 pandemic. We sought to understand what factors influenced people, especially those initially hesitant, to receive two or more vaccine doses within a year of the vaccine’s release.MethodsWe conducted longitudinal Web-based observational studies of 3,870 individuals. The surveys were conducted at four different time points: January 2021, June 2021, September 2021, and December 2021. In the baseline survey (January 2021), we assessed vaccination intention (i.e., “strongly agree” or “agree” [acceptance], “neutral” [not sure], and “disagree” or “strongly disagree” [hesitance]), and assumptions about coronavirus disease (COVID-19), COVID-19 vaccine, COVID-19-related health preventive behavior, and COVID-19 vaccine reliability. In subsequent surveys (December 2021), we assessed vaccination completion (i.e., ≥2 vaccinations). To investigate the relationship between predictors of COVID-19 vaccination completion, a multivariable logistic regression model was applied. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated while adjusting for gender, age, marital status, presence of children, household income category, and presence of diseases under treatment. In a stratified analysis, predictors were determined based on vaccination intention.ResultsApproximately 96, 87, and 72% of those who demonstrated acceptance, were not sure, or hesitated had been vaccinated after 1 year, respectively. Overall, significant factors associated with COVID-19 vaccine compliance included the influence of others close to the index participant (social norms) (AOR, 1.80; 95% CI, 1.56–2.08; p < 0.001), vaccine confidence (AOR, 1.39; 95% CI, 1.18–1.64; p < 0.001) and structural constraints (no time, inconvenient location of medical institutions, and other related factors) (AOR, 0.80; 95% CI, 0.70–0.91; p = 0.001). In the group of individuals classified as hesitant, significant factors associated with COVID-19 vaccine compliance included social norms (AOR, 2.43; 95% CI, 1.83–3.22; p < 0.001), confidence (AOR, 1.44; 95% CI, 1.10–1.88; p = 0.008), and knowledge (AOR, 0.69; 95% CI, 0.53–0.88; p = 0.003).DiscussionWe found that dissemination of accurate information about vaccines and a reduction in structural barriers to the extent possible enhanced vaccination rates. Once the need for vaccination becomes widespread, it becomes a social norm, and further improvements in these rates can then be anticipated. Our findings may help enhance vaccine uptake in the future.

Japan JP: Immunization: DPT: % of Children Aged 12-23 Months data was reported at 99.000 % in 2017. This stayed constant from the previous number of 99.000 % for 2016. Japan JP: Immunization: DPT: % of Children Aged 12-23 Months data is updated yearly, averaging 96.000 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 99.000 % in 2017 and a record low of 70.000 % in 1997. Japan JP: Immunization: DPT: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank: Health Statistics. Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

While vaccines are pivotal in combating COVID-19, concerns about side effects and complex procedures have hindered complete vaccination. Prior studies suggest that individuals defaulted to opt-out exhibit higher COVID-19 vaccination rates compared to those in opt-in systems. However, these studies were conducted in countries with a tolerant attitude towards vaccination and default changes, targeting specific age groups, and did not address potential deterrents like the increase in cancellation rates on the day, discomfort towards changing defaults, or the possibility of the opt-out effect being a one-time occurrence. Under the hypothesis that the default nature of the COVID-19 vaccination system influences attitudes towards vaccination even in countries conservative about vaccination and default changes like in Japan, we aimed to examine the differences in the first and second dose vaccination rates, cancellation rates, and the number of complaints between the opt-in and opt-out systems for COVID-19 vaccination. An email survey was conducted in 10 cities in A Prefecture, Japan. The results showed not only higher COVID-19 vaccination rates across all comparable age groups in the opt-out group but also a notably smaller decrease in the second-dose vaccination rate compared to the opt-in group, all achieved without any complaints about the system’s introduction. Consequently, it can be inferred that the potential inhibiting factors were largely overcome. Despite some limitations, such as regional specificity, the study suggests that opt-out systems might increase COVID-19 vaccination coverage without leading to significant cancellations or complaints, presenting a promising strategy to facilitate vaccination efforts.

As of June 30, 2023, Japan has administered around 310 doses of COVID-19 vaccine per 100 people, the highest in the Asia-Pacific region. In comparison, Papua New Guinea has administered only approximately 7.27 COVID-19 vaccine doses per 100 people.

Japan JP: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 96.000 % in 2016. This stayed constant from the previous number of 96.000 % for 2015. Japan JP: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 94.000 % from Dec 1980 (Median) to 2016, with 37 observations. The data reached an all-time high of 98.000 % in 2014 and a record low of 66.000 % in 1982. Japan JP: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

Immunization, DPT (% of children ages 12-23 months) in Japan was reported at 99 % in 2024, according to the World Bank collection of development indicators, compiled from officially recognized sources. Japan - Immunization, DPT (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on November of 2025.

BackgroundAccording to a recent paper by Gelfand et al., COVID-19 infection and case mortality rates are closely connected to the strength of social norms: “Tighter” cultures that abide by strict social norms are more successful in combating the pandemic than “looser” cultures that are more permissive. However, countries with similar levels of cultural tightness exhibit big differences in mortality rates. We are investigating potential explanations for this fact. Using data from Germany and Japan—two “tight” countries with very different infection and mortality rates—we examined how differences in socio-demographic and other determinants explain differences in individual preventive attitudes and behaviors.MethodsWe compared preventive attitudes and behaviors in 2020 based on real-time representative survey data and used logit regression models to study how individual attitudes and behaviors are shaped by four sets of covariates: individual socio-demographics, health, personality, and regional-level controls. Employing Blinder-Oaxaca regression techniques, we quantified the extent to which differences in averages of the covariates between Japan and Germany explain the differences in the observed preventive attitudes and behaviors.ResultsIn Germany and Japan, similar proportions of the population supported mandatory vaccination, avoided travel, and avoided people with symptoms of a cold. In Germany, however, a significantly higher proportion washed their hands frequently and avoided crowds, physical contact, public transport, peak-hour shopping, and contact with the elderly. In Japan, a significantly higher proportion were willing to be vaccinated. We also show that attitudes and behaviors varied significantly more with covariates in Germany than in Japan. Differences in averages of the covariates contribute little to explaining the observed differences in preventive attitudes and behaviors between the two countries.ConclusionConsistent with tightness-looseness theory, the populations of Japan and Germany responded similarly to the pandemic. The observed differences in infection and fatality rates therefore cannot be explained by differences in behavior. The major difference in attitudes is the willingness to be vaccinated, which was much higher in Japan. Furthermore, the Japanese population behaved more uniformly across social groups than the German population. This difference in the degree of homogeneity has important implications for the effectiveness of policy measures during the pandemic.

Japan JP: Immunization: HepB3: % of One-Year-Old Children data was reported at 99.000 % in 2019. Japan JP: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 99.000 % from Dec 2019 (Median) to 2019, with 1 observations. Japan JP: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Japan – Table JP.World Bank.WDI: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

To assess the public health impact and cost effectiveness of gender-neutral vaccination (GNV) versus female-only vaccination (FOV) with human papillomavirus (HPV) vaccination in Japan. We modeled the public health impact and cost effectiveness of GNV versus FOV to prevent HPV-associated diseases in Japan over the next 100 years. We used one-way sensitivity analyses to examine the impact of varying key model input parameters and conducted scenario analyses to explore the effects of varying the vaccination coverage rate (VCR) of each cohort. In the base-case analysis, GNV averted additional cancer cases (17,228 female/6,033 male) and deaths (1,892 female/1,849 male) compared to FOV. When all HPV-associated diseases were considered, GNV had an incremental cost-effectiveness ratio of ¥4,732,320 (US$35,987)/quality-adjusted life year gained compared to FOV. The model was most sensitive to the discount rate and the disutility associated with HPV-related diseases. GNV had greater relative public health benefits when the female VCR was lower and was cost effective at a female VCR of 30%. Immediate implementation of GNV would reduce the disease burden and mortality associated with HPV in Japan, and would be cost effective compared to FOV if the female VCR remains low (30%). Human papillomavirus (HPV) is a common sexually transmitted infection and, in Japan, the prevalence of HPV infection and the incidence of its associated diseases are high among both men and women. In the present manuscript we modeled the public health impact and cost effectiveness of gender-neutral vaccination versus female-only vaccination to prevent HPV-associated diseases in Japan over the next 100 years and found that immediate implementation of a gender-neutral vaccination strategy would reduce the burden and mortality associated with HPV in Japan.

As of March 16, 2022, there was a total of approximately 5.9 million confirmed cases of coronavirus disease (COVID-19) in Japan, with around 529 thousand people needing inpatient treatment.

Development of cases in Japan Generally, the increase of new COVID-19 cases recorded from January to March 2020 in Japan followed a slower trajectory as compared to, for example, China, Europe, or the United States of America. The first reported case of COVID-19 in Japan was confirmed on January 16, 2020, when a man that had returned from Wuhan city, China, was tested positive. The first transmission within Japan was recorded on January 28. The number of new cases then increased tenfold in February. April saw a further acceleration of the infection rate. Consequently, the Japanese government declared a nationwide state of emergency that month. The government announced a state of emergency for the second time in January 2021, the third time in April 2021, and the forth time in the July 2021.

Vaccine rollout The Japanese government started the distribution of COVID-19 vaccination in February 2021, mainly for medical professionals. The administration of vaccination for general citizens commenced in April for senior citizens. The vaccine rate of the population was just over 74.7 percent for second doses as of March 2022.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figure page.